|
|
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Number of employees : 33 625 people.
|
|
|
| 2019 | | USD (in Million) | % | | Pharmaceutical Products | 22,320 | 100% |
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | United States | 13,875 | 56.5% | 12,723 | 57% | -8.31% | | Europe | 4,231 | 17.2% | 3,765 | 16.9% | -11.02% | | Other Foreign Countries | 3,956 | 16.1% | 3,284 | 14.7% | -16.97% | | Japan | 2,494 | 10.2% | 2,548 | 11.4% | +2.16% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
956,957,372 |
954,971,024 |
99.8% |
487,000 |
0.1% |
99.8% |
|
|
|
| Name | Equities | % | | Lilly Endowment, Inc. | 111,132,343 |
11.6% | | Capital Research & Management Co. | 109,033,091 |
11.4% | | The Vanguard Group, Inc. | 67,446,882 |
7.05% | | The PNC Financial Services Group, Inc. | 50,000,000 |
5.23% | | PRIMECAP Management Co. | 39,627,957 |
4.14% | | SSgA Funds Management, Inc. | 36,698,045 |
3.84% | | Fidelity Management & Research Co. LLC | 28,189,577 |
2.95% | | Wellington Management Co. LLP | 26,990,778 |
2.82% | | Capital Research & Management Co. (International Investors) | 21,181,307 |
2.21% | | BlackRock Fund Advisors | 20,928,625 |
2.19% |
|
|
|
| Name | Equities | % | Valuation |
| Dicerna Pharmaceuticals, Inc. (DRNA) | 5,414,185 | 7.27% | 97,401,188 USD | | Zymeworks Inc. (ZYME) | 1,545,559 | 3.39% | 71,992,138 USD | | Avidity Biosciences, Inc. (RNA) | 2,169,396 | 5.78% | 61,068,497 USD | | NextCure, Inc. (NXTC) | 2,637,946 | 9.57% | 23,213,925 USD | | AC Immune SA (ACIU) | 0 | 0.0000% | |
|
| Company contact information |
|
Eli Lilly & Co. Lilly Corporate Center Indianapolis, IN 46285 Phone : +1.317.276.2000 Web : http://www.lilly.com |
|
|
|
Lilly hires external adviser for COVID-19 drug plant problems |
Sector Pharmaceuticals - NEC
Connections : Eli Lilly and Company |
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
